FLSM
NTLA icon

Frazier Life Sciences Management’s Intellia Therapeutics NTLA Stock Holding History

Frazier Life Sciences Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-203,684
Closed -$5.6M – 54
2024
Q1 		$5.6M Hold
203,684
– – 0.24% 44
2023
Q4 		$6.21M Hold
203,684
– – 0.33% 44
2023
Q3 		$6.44M Hold
203,684
– – 0.43% 39
2023
Q2 		$8.31M Hold
203,684
– – 0.5% 36
2023
Q1 		$7.59M Hold
203,684
– – 0.55% 36
2022
Q4 		$7.11M Hold
203,684
– – 0.44% 36
2022
Q3 		$11.4M Hold
203,684
– – 0.88% 27
2022
Q2 		$10.5M Hold
203,684
– – 1% 27
2022
Q1 		$14.8M Buy
+203,684
New +$17.3M 1.26% 28

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return